The 19th International Photodynamic Association (IPA) Congress concluded in Shanghai, marking seven days of academic excellence where global experts gathered to advance photodynamic medicine.
Asieris Pharmaceuticals (Stock Code: 688176.SH) showcased two globally innovative photodynamic products under the theme “Illuminating Tomorrow, Healing with Light”, demonstrating China’s leadership in medical innovation.
Global Experts Advance PDT Frontiers
Dr. Peter Hillemanns, pioneer in photodynamic therapy for gynecological precancerous lesions, emphasized in an interview:“PDT’s dual advantages of efficacy and non-invasiveness position it as the preferred treatment for cervical precancerous lesions – a paradigm shift with global potential.”
Dr. Hillemanns and Prof. Fei Chen (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences) co-chaired keynote sessions presenting APL-1702 data from the multinational APRICITY1study.
Innovative Products Draw Spotlight
- APL-1702: The world’s first and only non-invasive drug-device combination for cervical precancerous lesions, validated by a global Phase III trial, offers a fertility-friendly, non-invasive solution for cervical cancer prevention systems in China and globally.
- APL-1706: Globally the only approved imaging agent drug for assisting bladder cancer diagnosis/surgery. The combined use of APL-1706 and blue light cystoscopy (BLC) for non-muscle invasive bladder cancer (NMIBC) management is included in international and domestic guidelines/expert consensus.
APRICITY is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL. The study met its primary endpoint, together with a robust safety profile.
Note: As of this release date, APL-1702 has yet to be approved in China and is presented solely for display at the 2025 IPA. The information provided is not intended for patients. For more details about the condition, please consult a healthcare professional.
